Transversus Abdominus Plane Block in Living Donor Hepatectomy

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02708459

Acronym

TAP Donor

Enrollment

Registered

2016-03-15

Start date

2016-03-31

Completion date

2016-08-31

Last updated

2016-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Living Donor Hepatectomy

Brief summary

Comparing different drugs used in Transversus abdominus plane analgesia after donor hepatectomy. Patients will be divided into three groups; control group, Bupivecaine group, and Dexmedetomedine group according to the used drug

Detailed description

Transversus abdominus plane block for postoperative analgesia after donor hpatectomy surgery using three different drugs control group, Bupivecaine group, and Dexmedetomedine group

Interventions

DEVICEsurgically inserted Transversus abdominus plane catheter

at end of surgery, a surgeon will insert catheter in Transversus abdominus plane (TAP) between internal oblique muscle and Transversus abdominus muscle

DRUGIntravenous morphine

Boluses of intravenous morphine (2 mg) will be given to patients if Visual analogue scale (VAS) more than 3

DRUGBupevecaine

DRUGDexmedetomedine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Inclusion criteria

* all living hepatectomy donors in Mansoura liver transplantation program

Exclusion criteria

* refusal known sensetivity to used drugs

Design outcomes

Primary

Measure	Time frame
postoperative morphine (mg) consumption in 1st 48 hours	48 hours postoperative

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026